| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_188f66fce982c628c5013195dfc670ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32f57a53515b98afbb284cb39a2f17f7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4402 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-04 |
| filingDate |
2012-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27c3245aaa5b5042ffb6d179a0a60044 |
| publicationDate |
2012-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012170792-A1 |
| titleOfInvention |
Atazanavir metabolite derivatives |
| abstract |
The present invention provides a compound of Formula (I) or (II) or a pharmaceutically acceptable salt of any of the foregoing, wherein each of the variables is as defined herein. The compounds of the invention can be used in therapy, for example, to improve the efficacy of a therapeutic agent that is either (i) metabolized by a liver metabolic enzyme; (ii) transported by an efflux pump; or (iii) a combination of (i) and (ii), especially a HCV protease inhibitor or a HIV protease inhibitor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108069893-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11052087-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11078208-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10752636-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108084080-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10294234-B2 |
| priorityDate |
2011-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |